Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30484343 | 1.00 | PGR (0.33) | PGRAPPBACE1KDM1AWEE1 | |
| SCHEMBL24881003 | 0.95 | GAA (0.31) | PGR | |
| SCHEMBL24880941 | 0.90 | AR (0.30) | — | |
| SCHEMBL23364922 | 0.90 | AR (0.30) | — | |
| SCHEMBL21350109 | 0.90 | AR (0.30) | — | |
| SCHEMBL23364855 | 0.82 | WEE1 (0.33) | APPBACE1WEE1 | |
| SCHEMBL21332774 | 0.82 | WEE1 (0.33) | APPBACE1WEE1 | |
| SCHEMBL29828627 | 0.82 | WEE1 (0.33) | APPBACE1WEE1 | |
| SCHEMBL30594670 | 0.82 | WEE1 (0.33) | APPBACE1WEE1 | |
| SCHEMBL17441194 | 0.81 | KDM1A (0.34) | PGRKDM1AWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566612-A2 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Recurium IP Holdings, LLC (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3762385-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240391924-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2024-11-28 | — | — | US | disclosed |
| CN-117720541-A | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117285532-A | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-111902413-B | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-112142748-B | Pyrazolopyrimidine compound, and preparation method and application thereof | 上海医药集团股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023030388-A1 | 5-FLUORO-7H-PYRROLO[2,3-D] PYRIMIDINES COMPOUND AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023016417-A1 | 1,2-DIHYDRO-3H-PYRAZOL[3,4-D]PYRIMIDIN-3-ONE COMPOUND AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023280180-A1 | FUSED RING COMPOUND AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-11261192-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones | RECURIUM IP HOLDINGS, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2021-05-13 | — | — | US | disclosed |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2021-05-13 | — | — | US | disclosed |
| WO-2020259724-A2 | PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 上海医药集团股份有限公司 | 2020-12-30 | — | — | WO | disclosed |
| CN-112142748-A | Pyrazolone pyrimidine compound, preparation method and application thereof | 上海医药集团股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-111902413-A | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2020-11-06 | — | — | CN | disclosed |
| WO-2019173082-A1 | SUBSTITUTED L,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Zeno Royalties & Milestones, LLC (US) | 2019-09-12 | — | — | WO | disclosed |
| CN-105884752-B | And ring class gyrase and topoisomerase I V inhibitor | 山东轩竹医药科技有限公司 | 2018-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261192-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones | MKI67, BRCA1, CCNI | PGR 18/4885APP 3399/4885BACE1 3046/4885 |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | PGR 18/4885APP 3399/4885BACE1 3046/4885 |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | PGR 18/4885APP 3399/4885BACE1 3046/4885 |
| US-20240391924-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | PGR 18/4885APP 3399/4885BACE1 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.